• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacology, Biochemistry and Behavior >Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease.
【24h】

Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease.

机译：加兰他敏在大鼠中引起的口腔震颤：用于治疗阿尔茨海默氏病的拟胆碱药物的帕金森氏副作用模型。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Anticholinesterases are the most common treatment for Alzheimer's disease, and, in recent years, a new group of cholinesterase inhibitors (i.e. rivastigmine, galantamine, and donepezil) has become available. Although these drugs improve cognitive symptoms, they also can induce or exacerbate parkinsonian symptoms, including tremor. The present studies were conducted to determine if galantamine induces tremulous jaw movements, a rodent model of parkinsonian tremor, and to investigate whether these oral motor impairments can be reversed by co-administration of adenosine A(2A) antagonists. The first experiment demonstrated that systemic injections of galantamine (0.75-6.0 mg/kg I.P.) induced a dose-related increase in tremulous jaw movements in rats. In a second study, co-administration of the muscarinic antagonist scopolamine (0.0156-0.25 mg/kg I.P.) produced a dose dependent suppression of tremulous jaw movements induced by a 3.0 mg/kg dose of galantamine, indicating that galantamine induces these tremulous oral movements through actions on muscarinic acetylcholine receptors. In two additional studies, analyses of freeze-frame video and electromyographic activity recorded from the lateral temporalis muscle indicated that the local frequency of these galantamine-induced jaw movements occurs in the 3-7 Hz frequency range that is characteristic of parkinsonian tremor. In the final experiment, the adenosine A(2A) antagonist MSX-3 significantly attenuated the tremulous jaw movements induced by the 3.0mg/kg dose of galantamine, which is consistent with the hypothesis that co-administration of adenosine A(2A) antagonists may be beneficial in reducing parkinsonian motor impairments induced by anticholinesterase treatment.
机译：抗胆碱酯酶是阿尔茨海默氏病最常见的治疗方法，并且近年来，出现了一组新的胆碱酯酶抑制剂（如卡巴拉汀，加兰他敏和多奈哌齐）。尽管这些药物可以改善认知症状，但它们也可以诱发或加剧帕金森氏症，包括震颤。进行本研究以确定加兰他敏是否诱发颤动的颌骨运动，帕金森氏震颤的啮齿动物模型，并调查这些口服运动障碍是否可以通过共同使用腺苷A（2A）拮抗剂来逆转。第一个实验表明，全身注射加兰他敏（0.75-6.0 mg / kg I.P.）可引起大鼠颤抖性颌骨运动剂量相关的增加。在第二项研究中，毒蕈碱拮抗剂东pol碱（0.0156-0.25 mg / kg IP）的共同给药产生了剂量依赖性抑制作用，该抑制作用是由3.0 mg / kg剂量的加兰他敏引起的颤动下颌运动的抑制，表明加兰他敏诱导了这些颤动的口腔运动。通过对毒蕈碱型乙酰胆碱受体的作用。在另外两项研究中，对从颞外侧肌记录的定格视频和肌电图活动的分析表明，这些加兰他敏诱导的颌骨运动的局部频率发生在帕金森氏震颤的特征性3-7 Hz频率范围内。在最后的实验中，腺苷A（2A）拮抗剂MSX-3显着减弱了3.0mg / kg剂量的加兰他敏引起的颤动的颌骨运动，这与腺苷A（2A）拮抗剂共同给药可能引起的假说相符。有助于减少抗胆碱酯酶治疗引起的帕金森氏症运动损害。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号